Best Peptides for Weight Loss & Obesity

Peptides studied for weight management and obesity treatment, from FDA-approved GLP-1 agonists to research compounds targeting fat metabolism.

Recommended Peptides (6)

Semaglutide

FDA Approved

GLP-1 Receptor Agonists

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the nat...

Type 2 diabetesChronic weight managementCardiovascular risk reduction

Tirzepatide

FDA Approved

GLP-1 Receptor Agonists

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. It produces the most signi...

Type 2 diabetesChronic weight managementObstructive sleep apnea

Retatrutide

In Clinical Trials

GLP-1 Receptor Agonists

Retatrutide is an investigational triple-action peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, it produc...

Obesity treatmentType 2 diabetesNASH/MAFLD

Liraglutide

FDA Approved

GLP-1 Receptor Agonists

Liraglutide is a GLP-1 receptor agonist with 97% structural similarity to human GLP-1. It was one of the first long-acting GLP-1 drugs, paving the way...

Type 2 diabetesWeight management

AOD-9604

Compoundable (Rx)

Fat Loss Peptides

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone specifically designed for fat loss. It retains the fat-reducing action o...

Fat lossMetabolic supportBody composition

MOTS-c

Compoundable (Rx)

Metabolic Peptides

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene. It functions as an exercise mimetic, activating AMPK pathways similar to p...

Exercise mimeticMetabolic optimizationInsulin sensitivity

Quick Comparison

Peptide	Class	Legal Status (USA)	Evidence	Administration	Dosage
Semaglutide	GLP-1 Receptor Agonists	FDA Approved	AStrong Evidence	subcutaneous, oral	0.25mg–2.4mg weekly (injectable); 3mg–14mg daily (oral)
Tirzepatide	GLP-1 Receptor Agonists	FDA Approved	AStrong Evidence	subcutaneous	2.5mg–15mg weekly
Retatrutide	GLP-1 Receptor Agonists	In Clinical Trials	BModerate Evidence	subcutaneous	1mg–12mg weekly (Phase 2 dosing)
Liraglutide	GLP-1 Receptor Agonists	FDA Approved	AStrong Evidence	subcutaneous	0.6mg–3.0mg daily
AOD-9604	Fat Loss Peptides	Compoundable (Rx)	CPreliminary Evidence	subcutaneous, oral	250-500mcg daily
MOTS-c	Metabolic Peptides	Compoundable (Rx)	CPreliminary Evidence	subcutaneous	5-10mg weekly